[ad_1] HONG KONG, Nov. 7, 2024 /PRNewswire/ — At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 – 10, Akeso Biopharma (9926. HK) presented […]
Tag: Akeso
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
[ad_1] HONG KONG, Oct. 31, 2024 /PRNewswire/ — Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the AK112-309 trial, a randomized, controlled, multicenter Phase III registration study for […]
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
[ad_1] HONG KONG, Oct. 30, 2024 /PRNewswire/ — Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous […]
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
[ad_1] Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds HONG KONG, Oct. 13, 2024 /PRNewswire/ — Akeso Biopharma (9926. HK) (“Akeso”, the “Company” ) announced that it has successfully […]
Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
[ad_1] HONG KONG, Sept. 16, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line […]
